(firstQuint)Study of Idursulfase-beta (GC1111) in Hunter Syndrome.

 This is a randomized, double-blind, active-controlled, dose-ranging study, where patient will receive one of the three doses of GC1111 (0.

5 mg/kg, 1.

0 mg/kg, and 1.

5 mg/kg) or ELAPRASE 0.

5 mg/kg.

 Approximately 20 patients will be administrated each study drug once every week as an iv infusion for 24 weeks.

 Efficacy of GC1111 will be evaluated in Six-Minute Walk Test (6MWT), urine Glycosaminoglycans(uGAG), liver and spleen volume, percent predicted Forced Vital Capacity(FVC), and cardiac size and function.

 Also immunogenicity, Pharmacokinetics(PK) and safety will be evaluated.

.

 Study of Idursulfase-beta (GC1111) in Hunter Syndrome@highlight

This study evaluates the efficacy and safety of three doses of GC1111 in patients with Hunter Syndrome.

 Participants will be randomized to one of three doses of GC1111 or comparator.

